Work

Determination of the maximum tolerated dose (MTD) of the CNS penetrant tyrosine kinase inhibitor (TKI) tesevatinib administered in combination with trastuzumab in HER2+ patients with metastatic breast cancer (BC).

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.514

Authors: Nancy U. Lin, Rachel A. Freedman, Kathy Miller, Komal L. Jhaveri, David A. Eiznhamer, Mark S. Berger, Erika Paige Hamilton

Institutions: Dana-Farber Cancer Institute, Indiana University Health, Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, New York University, Kadmon Corporation (United States), Sarah Cannon, Tennessee Oncology

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2736207382

Cites:

Cited by: 14

Related to: 10